A new study indicated that daratumumab, an anti-CD38 monoclonal antibody, could inhibit AML disease progression via a mechanism involving blocking mitochondrial transfer from MSCs to AML blasts.176 As malignant tumors develop as part of a high-metabolic and invasive complex, future studies are required to investigate the profound effect of mitochondrial acquisition on the respiratory metabolism of cancer cells and to explore a valid approach for the inhibition of mitochondrial transfer in the TME with minimal side effects. This evidence concerns the gene CD38 and cancer.